Connect Biopharma to Present at the San Francisco Biotech Showcase in January
Connect Biopharma (Nasdaq: CNTB) will present a corporate update led by CEO Zheng Wei, PhD, on January 9, 2023, at 9:00 am PST during the Biotech Showcase. The event takes place in San Francisco from January 9-11, 2023. Key executives, including CFO Steven Chan and CMO Chin Lee, will also be available for investor meetings. Connect Biopharma focuses on developing T cell-driven therapies for inflammatory diseases, with product candidates like CBP-201 for atopic dermatitis, CBP-307 for ulcerative colitis, and CBP-174 for pruritus.
- None.
- None.
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma will present a corporate update on January 9, at 9:00 am PST, during the upcoming Biotech Showcase taking place in person January 9 – 11, 2023.
Connect Biopharma’s senior leadership team, including Chief Financial Officer, Steven Chan and Chief Medical Officer, Chin Lee, MD, MPH will also be available for meetings with potential investors and partners in San Francisco during the Biotech Showcase / JP Morgan Healthcare Conference week.
Meetings can be requested through the Biotech Showcase Partnering Platform or by contacting Connect Biopharma at investors@ConnectPharm.com.
About Connect Biopharma Holdings Limited
Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis. The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis.
#BiotechShowcase
INVESTOR CONTACT:
Ina McGuinness
805.427.1372
imcguinness@connectpharm.com
MEDIA
Deanne Eagle
917.837.5866
deanne@mcguinnessIR.com
FAQ
What is the date of Connect Biopharma's corporate update at the Biotech Showcase?
Who will present at the Biotech Showcase for Connect Biopharma?
What are the main products being developed by Connect Biopharma?
Where is the Biotech Showcase taking place?
How can investors request meetings with Connect Biopharma during the Biotech Showcase?
